Study: PET useful for distinguishing forms of dementia

04/22/2013 | MolecularImaging.net

PET imaging with 11C-dihydotetrabenazine to determine striatal dopamine terminal integrity and with 11C-Pittsburgh compound B to measure cerebral amyloid accumulation can help classify mild cognitive impairment as it develops into Alzheimer's disease, frontotemporal dementia or Lewy body dementia, according to a study published in The Journal of Nuclear Medicine. The dual-target PET technique identified 18 patients with Alzheimer's pathology, seven with FTD characteristics and two with signs of LBD, the study said. Most went on to develop dementia. Having a model for distinguishing between types of MCI could enhance future clinical trials, researchers said.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC